Camurus AB
F:7CA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Camurus AB
F:7CA
|
SE |
|
Viohalco SA
XBRU:VIO
|
BE |
|
G
|
Groep Brussel Lambert NV
LSE:0IN2
|
BE |
|
T
|
Telekom Austria AG
XMUN:TA1
|
AT |
Camurus AB
Camurus AB is a Swedish biopharma company that develops long-acting medicines built on its FluidCrystal drug-delivery technology. Its main idea is to turn existing medicines into injections or implants that release medicine slowly over time, so patients do not need to take them as often. The company sells prescription treatments and also earns money by licensing its technology and partnering with other drug makers. Its best-known products are used mainly in opioid dependence and other chronic conditions where steady dosing matters. The company works with hospitals, addiction clinics, specialist doctors, and pharmaceutical partners that need drug formulations with longer-lasting effects than standard pills or injections. For patients and doctors, the value is simpler dosing and more predictable treatment over time. Camurus makes money in two ways: direct sales of its own medicines where it has commercial rights, and licensing or collaboration payments from partners that use its delivery platform. What makes the business different is that it is not just discovering new drugs from scratch; it is also re-engineering how medicines are delivered, which can extend the useful life of established therapies and create a recurring role in specialty drug markets.
Camurus AB is a Swedish biopharma company that develops long-acting medicines built on its FluidCrystal drug-delivery technology. Its main idea is to turn existing medicines into injections or implants that release medicine slowly over time, so patients do not need to take them as often. The company sells prescription treatments and also earns money by licensing its technology and partnering with other drug makers.
Its best-known products are used mainly in opioid dependence and other chronic conditions where steady dosing matters. The company works with hospitals, addiction clinics, specialist doctors, and pharmaceutical partners that need drug formulations with longer-lasting effects than standard pills or injections. For patients and doctors, the value is simpler dosing and more predictable treatment over time.
Camurus makes money in two ways: direct sales of its own medicines where it has commercial rights, and licensing or collaboration payments from partners that use its delivery platform. What makes the business different is that it is not just discovering new drugs from scratch; it is also re-engineering how medicines are delivered, which can extend the useful life of established therapies and create a recurring role in specialty drug markets.
Record Revenue: Camurus posted all-time high quarterly revenue of SEK 676 million, up 52% year-on-year, driven by strong product sales and royalty income.
Profit Surge: Profit before taxes reached SEK 307 million, up 195% versus last year, representing 45% of sales.
Buvidal Growth: Buvidal patient numbers rose to around 65,000, with steady growth in Europe and expansion into new markets like Portugal.
Brixadi Momentum: Brixadi royalties in the U.S. doubled year-on-year and climbed 21% quarter-on-quarter, signaling recovery from Q1 headwinds.
Oczyesa EU Approval: Oczyesa (CAM2029) gained European Commission approval for acromegaly, with launches in first EU markets expected in early 2025.
Pipeline Progress: The POSITANO study in polycystic liver disease met its primary endpoint, and all patients entered the 2.5-year extension.
Lilly License Deal: Signed a key license agreement with Eli Lilly for long-acting incretins, including up to SEK 290 million in milestone payments and royalties.
Guidance Maintained: Full-year guidance remains unchanged; management expects growth for both Buvidal and Brixadi in H2 2025.
